Detalles de la búsqueda
1.
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Prostate
; 84(9): 888-892, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561317
2.
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Cancer
; 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564301
3.
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI.
JCO Precis Oncol
; 8: e2300574, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38781543
4.
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy.
Eur Urol Oncol
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38735779
5.
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Prostate Cancer Prostatic Dis
; 2023 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37460732
6.
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Prostate Cancer Prostatic Dis
; 2023 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37620429
Resultados
1 -
6
de 6
1
Próxima >
>>